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Abstract
Background: Kawasaki disease (KD) of unknown immunopathogenesis is an acute febrile systemic vasculitis and the leading
cause of acquired heart diseases in childhood. To search for a better strategy for the prevention and treatment of KD, this
study compared and validated human KD immunopathogenesis in a mouse model of Lactobacillus casei cell wall extract
(LCWE)-induced coronary arteritis.
Methods: Recruited subjects fulfilled the criteria of KD and were admitted for intravenous gamma globulin (IVIG) treatment
at the Kaohsiung Chang Gung Memorial Hospital from 2001 to 2009. Blood samples from KD patients were collected before
and after IVIG treatment, and cardiovascular abnormalities were examined by transthoracic echocardiography. Wild-type
male BALB/c mice (4-week-old) were intraperitoneally injected with LCWE (1 mg/mL) to induce coronary arteritis. The
induced immune response in mice was examined on days 1, 3, 7, and 14 post injections, and histopathology studies were
performed on days 7 and 14.
Results: Both human KD patients and LCWE-treated mice developed coronary arteritis, myocarditis, valvulitis, and
pericarditis, as well as elevated plasma levels of interleukin (IL)-2, IL-6, IL-10, monocyte chemoattractant protein (MCP)-1,
and tumor necrosis factor (TNF)-a in acute phase. Most of these proinflammatory cytokines declined to normal levels in
mice, whereas normal levels were achieved in patients only after IVIG treatment, with a few exceptions. Toll-like receptor
(TLR)-2, but not TLR4 surface enhancement on circulating CD14
+ monocytes, was augmented in KD patients before IVIG
treatment and in LCWE-treated mice, which declined in patients after IVIG treatment.
Conclusion: This result suggests that that not only TLR2 augmentation on CD14
+ monocytes might be an inflammatory
marker for both human KD patients and LCWE-induced CAL mouse model but also this model is feasible for studying
therapeutic strategies of coronary arteritis in human KD by modulating TLR2-mediated immune activation on CD14
+
monocytes.
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Introduction
Kawasaki disease (KD) is a common cause of systemic vasculitis
in young children, mostly affecting medium- and large-sized
vessels. Coronary arteritis/coronary artery lesions (CALs), such as
coronary artery ectasia and aneurysms, are the major devastating
abnormalities associated with KD [1–2]. KD with CALs is one of
the leading causes of acquired heart diseases in childhood [3–4].
Several clinical and pathological studies have indicated persistent
vascular remodeling in these CALs [5–7]. Acute myocardial
infarction or sudden death in young adults with childhood KD has
been reported [8–9]. The current standard treatment with high-
dose intravenous gamma globulin (IVIG, 2 g/kg) lowers the
incidence of CALs from 25% to approximately 5% in cases of
transient coronary ectasia and to 1% in cases of giant coronary
aneurysms [10–11]. Nevertheless, resistance to the initial dose of
IVIG is noted in 13–23% of KD patients with altered immune
responses [12–13]. Since Dr. Kawasaki’s first report on KD in
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e386351967, several immune alterations associated with KD have been
reported [14–17]. The process by which systemic activation of the
immune system progresses to leukocyte infiltration of coronary
arteries and carditis in KD remains unclear.
Owing to the difficult access to coronary artery samples from
human KD patients, several animal models, including mouse,
rabbit, swine, and dog are employed to examine its immuno-
pathogenesis [18–23]. Lactobacillus casei cell wall extract (LCWE) is
commonly used to induce KD in animal models, inducing murine
coronary arteritis similar to CALs associated with human KD
[24]. Rosenkranz et al. [25] previously reported the importance of
toll-like receptor (TLR)-2 signaling in LCWE-induced coronary
arteritis by using TLR2
2/2 knockout mice. In addition, we
previously found that TLR2 augmentation on LCWE-treated
RAW 264.7 cells–a murine monocyte/macrophage cell line–was
positively correlated with LCWE-induced IL-6, MCP-1, and
TNF-a upregulation [26]. However, it is possible that different
host species may react differently, thereby posing a significant
problem. For example, LCWE induces coronary arteritis in mice,
whereas LCWE was reported to cause arthritis but not
cardioangitis in rats [27]. Despite murine TLRs showing highly
conserved homology with human TLRs, TLR2 regulation
between mice and human differs considerably [28]. Therefore,
we attempted to elucidate the involvement of TLRs in both
human KD and LCWE-treated mice.
In this study, we further validated the cardiovascular pathologic
lesions, immune alterations, and TLR2 expression in human KD
patients in comparison with those in LCWE-treated mice. The
common features of TLR2 augmentation on CD14
+ monocytes,
immune abnormalities and cardiovascular lesions suggest that not
only TLR2 augmentation on CD14
+ monocytes might be an
inflammatory marker for both human KD patients and LCWE-
induced CAL mouse model but also this model is suitable for
investigating the immunopathogenesis of human KD, and it might
lead to potential therapeutic strategies for the prevention or
treatment of KD in patients with CALs.
Results
Coronary Arteritis, Myocarditis, Valvulitis, and Pericarditis
in KD Patients
We studies 334 patients, including 223 boys (66.77%) and
111 girls (33.23%), at the mean age of 20.861.02 months, with a
discharged diagnosis of KD from 2001 to 2009 at the Kaohsiung
Chang Gung Memorial Hospital, Taiwan. There were no cases of
mortality in this study. According to echocardiography studies,
118 patients (35.33%) had CAL formation, 7 patients had
myocarditis (2.10%), 2 patients had pericarditis (0.60%), and
70 patients had valvulitis (20.96%) (Table 1).
Significant Increase in Systemic Pro-inflammatory
Responses in KD Patients
The plasma levels of IL-2, IL-6, IL-10, MCP-1 and TNF-a were
studied in 39 human KD patients before (Pre-IVIG) and after
IVIG (Post-IVIG) treatment in pairs and in 15 control patients
(Figure 1). Plasma levels of IL-6 were significantly higher in KD
patients before IVIG treatment (33.96610.92 pg/ml) than those
in the control patients (2.4960.18 pg/ml) and those after IVIG
treatment (10.8561.85 pg/ml) (P=0.006, P=0.029, respectively).
Similarly, MCP-1 levels were higher in KD patients before IVIG
(328.26641.32 pg/ml) than those in control patients
(32.7363.48 pg/ml) and those after IVIG (142.34612.58 pg/
ml) (P,0.001, P,0.001, respectively). TNF-a levels were higher in
KD patients before IVIG (33.1863.08 pg/ml) than those in
control patients (13.8361.08 pg/ml) and those after IVIG
(18.2861.77 pg/ml) (P,0.001, P,0.001, respectively). Interest-
ingly, IL-2 levels were higher in KD patients before IVIG
(13.5261.38 pg/ml) when compared to control levels
(3.0360.62 pg/ml) (P,0.001), but remained significantly elevated
even after IVIG (24.9562.78 pg/ml) (P,0.001). IL-10 levels were
higher in KD patients before IVIG (18.3162.26 pg/ml) when
compared to control levels (7.6160.84 pg/ml) (P,0.001) and
remained higher after IVIG (14.1661.99 pg/ml).
Significant Augmentation of TLR2 Surface Expression on
Peripheral Monocytes in KD Patients
Flow cytometry on PBLs using mean fluorescence intensity
(MFI) was performed to analyze the surface expression of TLR2
and TLR4 in KD patients. The percentages of human monocytes
expressing surface TLR2 varied widely, ranging from 7.76% to
70.08% in control patients (n=6, controls), 4.2% to 91.61% in
KD patients before IVIG (n=12, Pre-IVIG KD), and 3.78% to
57.25% in KD patients after IVIG treatment (n=8, Post-IVIG
KD) (Figure 2A and B). Only a few neutrophils and even fewer
lymphocytes expressed TLR2 on their surface. Except for some
monocytes with low intensity expression of surface TLR4, there
were few TLR4-positive circulating neutrophils and lymphocytes
in KD patients and control patients. Furthermore, TLR2
enhancement over CD14
+ monocytes was significantly augmented
in KD patients before IVIG treatment compared to that in control
patients (P=0.004), which significantly decreased in patients after
IVIG treatment (P=0.005) (Figure 2C).
Immune Alterations in LCWE-treated Mice
Next, IL-2, IL-6, IL-10, MCP-1, and TNF-a levels were
measured in the plasma from mice sacrificed after LCWE
treatment for 1, 3, 7, and 14 days (n=9 except n=5 for IL-2,
per time point) (Figure 3). Plasma IL-6 and IL-2 levels in LCWE-
treated mice on days 1 and 3 were significantly higher than those
in controls (n$7, per time point) (P=0.003, P=0.037, respectively
in IL-6; P=0.009, P=0.007, respectively in IL-2). On days 7 and
14, both plasma IL-6 and IL-2 levels in LCWE-treated mice
declined and were not statistically different from those in controls.
Similarly, LCWE-treated mice exhibited considerably higher
plasma MCP-1 levels than control levels on post-injection days
1, 3, and 7 (P,0.001, P=0.024, P=0.011, respectively). On day
14, plasma MCP-1 levels in LCWE-treated mice were higher, but
not significantly higher, than those in controls. Further, the plasma
level of TNF-a in LCWE-treated mice on day 1 was higher than
those in controls (P,0.001). On days 3, 7 and 14, plasma levels of
Table 1. Cardiovascular abnormalities in Kawasaki disease
(KD) patients and Lactobacillus casei cell wall extract (LCWE)-
treated mice.
Types of Lesions
Arteritis Myocarditis Pericarditis Valvulitis
Human KD patients
N=334 118 7 2 70
35.33% 2.10% 0.60% 20.96%
LCWE-treated Mice
N=23 20 12 7 5
86.96% 52.17% 30.43% 21.74%
doi:10.1371/journal.pone.0038635.t001
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levels measured in controls. The plasma IL-10 level was
significantly increased in LCWE-treated mice on day 3
(P=0.003), but spontaneous recovery to the basal level was
observed at later time points.
Significant Augmentation of TLR2 Expression on
Monocytes of LCWE-treated Mice
In LCWE-treated or PBS-treated mice, the majority of
circulating monocytes and neutrophils, as well as a few lympho-
cytes, expressed surface TLR2 with stronger intensity observed on
monocytes than on neutrophils (Figure 4A). In contrast, TLR4/
MD2 surface expression on monocytes, neutrophils, and lympho-
cytes was much lower than TLR2 expression, regardless of LCWE
treatment. To confirm the TLR2 expression on monocytes in
LCWE-treated mice, we used dual staining of CD14 and TLR2 to
track the kinetic expression of TLR2 on CD14
+ monocytes on
days 1, 3, 7, and 14 post injection (n=7, per time point). The
results indicated that TLR2 surface expression on CD14
+
monocytes significantly increased on days 3, 7 and 14 in
LCWE-treated mice compared to that in the control mice
(P=0.035, P=0.004, P=0.002, respectively) (Figure 4B). In
addition, it was found that CD14
+ monocytes significantly
increased in LCWE-treated mice when compared to control
CD14
+ monocytes after 3 days (P=0.004 on day 3, P=0.002 on
day 7, P=0.006 on day 14) (Figure 4C).
Cardiovascular Lesions in LCWE-treated Mice
Heart tissues from 23 mice treated with LCWE (LCWE-treated
mice) were subjected to H&E examination on days 7 (n=11) and
14 (n=12) post injection and compared to those of the controls.
None of the controls treated with PBS (n=18) developed any
pathological lesion on days 7 and 14. The overall induction rate of
arteritis was 86.96% (20/23); myocarditis, 52.17% (12/23);
pericarditis, 30.43% (7/23); and valvulitis, 21.74% (5/23)
(Table 1). Arteritis was most frequently associated with some
mononuclear cell and neutrophil infiltration in the perivascular/
adventitial region of the aorta and coronary artery on day 7
(Figure 5). Some mice showed more prominent infiltration
invading into the myocardium (Figure 5C), aortic valve
(Figure 5B), or pericardium (Figure 5G and F). Furthermore, no
inflammatory lesion was observed in the liver, lung, kidney, or
spleen.
Discussion
The results of this study demonstrate the similar features of
monocyte TLR2 augmentation, immune abnormalities and
cardiovascular lesions in human KD patients and LCWE-treated
mice. KD, a childhood cardiovascular disease, leads to chronic
and persistent vascular inflammation of coronary arteries until
adulthood. Since the importance of TLR2 in LCWE-mediated
arteritis, the aim of our study was to assess the involvement of
TLR2 on CD14
+ monocytes in both human KD and LCWE-
induced arteritis mice, and to further validate the translational
application of this mouse model for investigating human KD.
TLR2 augmentation on CD14
+ monocytes is a distinct feature
shared by KD patients and LCWE-treated mice, although TLR2
expression is a little dissimilar between human and mice. In
contrast, no differential expression of TLR4 was observed between
KD patients and control patients, or between LCWE-treated mice
and PBS-control mice. Meanwhile, an increase in circulating
CD14
+ monocytes was found in LCWE-treated mice, a result
compatible with those of our clinical study [29] showing that
persistent monocytosis after IVIG therapy was associated with
Figure 1. Immune abnormalities in human patients with Kawasaki disease (KD). Plasma levels of interleukin (IL)-6, monocyte
chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)-a, IL-2, and IL-10, assessed by Luminex technology, were significantly increased in KD
patients before intravenous gamma globulin (Pre-IVIG), when compared to those in controls. IL-6, MCP-1, and TNF-a were significantly suppressed
after IVIG treatment (Post-IVIG), but IL-2 and IL-10 responded differently. Values are expressed as mean6SEM; n=39 in paired KD patients, n=15 in
control patients. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0038635.g001
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augmentation on RAW 264.7 cells might be indicative of strong
inflammation of monocytes/macrophages due to this augmenta-
tion was positively correlated with LCWE-induced IL-6, MCP-1,
and TNF-a upregulation [26]. Meanwhile, these upregulation of
proinflammatory cytokines/chemokines could be suppressed in
vitro by using TLR2 but not TLR4 neutralizing antibody (Figure
S1). Taken together, TLR2 augmentation on monocytes may
serve an inflammatory marker in both human KD patients and the
LCWE-induced arteritis mouse model, and TLR2 may play a
crucial role in the immunopathogenesis of human KD as in the
LCWE-induced arteritis mouse model [25].
Among 334 recruited KD patients, approximately one-third
and one-fifth of them developed coronary arteritis and valvulitis,
respectively. Very few KD patients had myocarditis (2.1%) and
pericarditis (0.6%). The rate of CALs, valvulitis, myocarditis, and
pericarditis/pericardial effusion had been reported ranging from
5% to 46%, 4.2% to 53%, 15% to 65%, and 30%, respectively,
revealed by different diagnostic modalities [30–32]. It is notewor-
thy that these 4 types of cardiovascular lesions were also observed
in LCWE-treated mice. However, the lower incidence of
myocarditis and pericarditis in our KD patients may partly result
from the method of diagnosis. All instances of pericarditis in mice
were diagnosed by histopathology, and pericarditis always
occurred in association with myocarditis invading into the
pericardium. While isolated pericardial effusion was not visually
seen in LCWE-treated mice, it was detected in a few KD patients
by echocardiography. Moreover, subtle/occult myocarditis would
not cause significant myocardial depression and impaired ejection
fraction detectable by echocardiography. This subtlety might
cause an underestimation of the incidence of myocarditis in KD
patients, especially for the milder form of myocarditis. Taken
together, LCWE could efficiently induce mice to develop the same
cardiovascular lesions as those in human KD patients. This
mimicry warrants the investigation of the underlying mechanism
of the LCWE-induced arteritis mouse model and its experimental
application in translational study.
In order to survey the immunopathogenesis of KD, some
immune responses were assessed both in KD patients and LCWE-
treated mice. Marked elevation of IL-6, MCP-1, and TNF-a
suggested a robust systemic inflammation in the early stages in
both human disease and the mouse model. In human KD patients,
these 3 cytokines significantly declined after IVIG treatment but
remained statistically higher than those in controls, though
samples from KD patients without IVIG treatment were
unavailable. CALs in KD patients often occurred before the
systemic inflammation completely subsided. In contrast, a
spontaneous recovery of these 3 cytokines occurred in LCWE-
treated mice, nearly reaching basal levels without any treatment
during 3 and 7 days post injection, which was then followed by the
Figure 2. TLR2 and TLR4 surface expression on peripheral blood leukocytes (PBLs) in human KD patients. (A) Representative
histograms showed surface expression of TLR2 and TLR4 by mean fluorescence intensity (MFI) on peripheral monocytes, neutrophils, and
lymphocytes in KD patients before IVIG treatment and control patients. (B) The representative histogram displayed surface expression of TLR2 by MFI
on peripheral CD14
+ monocytes in human KD patients before and after IVIG treatment as well as those in control patients. (C) TLR2 expression over
CD14
+ monocytes are expressed as mean6SEM by MFI. n=6 in controls; n=12 Pre-IVIG; n=8 Post-IVIG. **P,0.01.
doi:10.1371/journal.pone.0038635.g002
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increases in cardiac IL-6, MCP-1, and TNF-a [26]. Apparently, a
spatial and temporal differentiation between systemic and cardiac
inflammation were observed in LCWE-induced arteritis mice [26].
These results may imply the same differentiation in human KD
and thus, highlight the necessity of this animal model to study KD.
Alterations in systemic IL-2 and IL-10 differ between human
KD patients and LCWE-treated mice. IL-2 significantly increased
after IVIG treatment in humans, whereas LCWE-treated mice
showed a spontaneous decline in plasma level of IL-2 at 7 days
post injection. IL-10 levels before and after IVIG treatment did
not differ in human KD, whereas elevation in IL-10 increased in
the early phase after LCWE treatment and returned to basal levels
thereafter. IL-2 is a leukocytotrophic cytokine, leading to T-cell
activation. The role of T cell activation in pathogenesis of human
KD remains an area of intense research. Persistent elevation of
systemic IL-2 even 3–7 days after IVIG treatment might be
indicative of continuing T cell activation. However, a spontaneous
recovery of systemic IL-2, like other cytokines, could not account
for the local cardiac inflammation in the mouse model. In
agreement with a study performed by Schulte et al. [33], we also
found that the involvement of T cells contributed to the local
cardiac inflammation, as assessed by immunohistochemistry,
showing CD3- and CD4-positive cells around the cardiac
infiltration, concomitant with increased mRNA levels of interfer-
on-c and IL-17A (data not shown).
In conclusion, we addressed the involvement of CD14
+
monocytes and their TLR2 enhancement as well as dynamic
immune responses and cardiovascular lesions in both human KD
patients and LCWE-treated mice. These shared features suggest
that TLR2 augmentation may be a candidate indicator of CD14
+
monocyte activation in human KD patients and LCWE-treated
mice. In addition, the LCWE-induced arteritis mouse model is
feasible for studying the immunopathogenesis of coronary arteritis
in human KD and for determining methods for the prevention of
coronary arteritis in human KD by blocking TLR2-mediated




"The study protocol involving human participants conformed to
the Declaration of Helsinki and was approved by the Institute
Review Board of Kaohsiung Chang Gung Memorial Hospital
(Permit number: 96-0279B, 96-0359B, and 99-4059B). All human
subjects gave permission through the informed written consent
form from the next of kin, or guardians on the behalf of the
minors/children participants involved in our study. All clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki.
All animal experiments were performed in accordance with
legislation on the protection of animals and were approved (Permit
number: 2009071301, 2007032602) by the animal care committee
at Chang Gung Memorial Hospital". All procedures were
performed under anesthesia, and all efforts were made to minimize
suffering.
Patients and Samples
All subjects studied were children diagnosed with KD, who were
admitted for IVIG treatment at the Kaohsiung Chang Gung
Memorial Hospital from 2001 to 2009. Blood samples from
control patients admitted for upper and/or lower respiratory tract
infections were also included for comparison. The echocardiog-
raphy reports were reviewed retrospectively. CAL/arteritis was
Figure 3. Immune abnormalities in the Lactobacillus casei cell wall extract (LCWE)-treated mice. Plasma levels of IL-6, MCP-1, TNF-a, IL-2,
and IL-10 were assessed by Luminex technology. IL-2, IL-6, MCP-1 and TNF-a were significantly increased early after LCWE stimulation and
spontaneously declined to basal levels during days 3 and 7 post injection. In contrast, IL-10 was significantly elevated at day 3 post injection. Values
are expressed as mean6SEM; n=9 in LCWE-treated mice; n$7 in PBS-treated mice, per time point for all, except n=5 for IL-2 per group per time
point. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0038635.g003
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3 mm (4 mm if the subject was over the age of 5 years) or a
segment with an internal diameter at least 1.5 times larger than
that of an adjacent segment by echocardiogram [34–35].
Myocarditis was defined as a left ventricle ejection fraction of
#54%, and pericarditis was defined as acute phase pericardial
effusion. Valvulitis was defined as (1) aortic valve regurgitation and
mitral valve regurgitation at acute and regressed during follow-up
and/or (2) tricuspid valve regurgitation greater than moderate
grade at the acute phase that regressed during follow-up.
LCWE Preparation
LCWE was prepared as previously described [26]. Briefly, cells
of Lactobacillus casei (ATCC 11578, Bioresource Collection and
Research Center, Taiwan) were first cultured in Lactobacillus
MRS broth (Difco, Detroit, MI) at 37uC. After harvested, the cells
were treated overnight with 4% SDS (Sigma-Aldrich, St. Louis,
MO), followed by sequentially incubated with 250 mg/ml RNase,
DNaseI, and trypsin (Sigma-Aldrich). The final pellet was then
sonicated (5 g packed wet weight in 15 ml PBS) for 2 hours at a
pulse setting of 9 second pulse/5 second pause at 20 kHz
frequency (Vibra Cell
TM, Sonics & Materials Inc., Newtown,
CT). Following 1-hour centrifugation at 20,0006g, the superna-
tant concentration was determined on the basis of its rhamnose
content by using a phenol-sulfuric acid colorimetric assay [36].
The endotoxin concentration of this preparation was ,1.5 pg/mg
(data not shown), as determined by the Limulus amoebocyte lysate
assay (Associates of Cape Cod Inc., East Falmouth, MA).
Mice and Animal Model of Coronary Arteritis
Wild-type BALB/c mice, purchased from the National Labo-
ratory Animal Center, Taiwan, were used in this study. Four-
week-old male mice were intraperitoneally injected with either
1 ml of PBS alone as controls or PBS containing 1 mg of LCWE
[24,26] as treatment mice. Heart tissue sections were obtained for
examination of coronary arteritis and myocarditis on post-
injection days 7 and 14 because infiltrates began in the adventitia
of coronary arteries as early as day 3–7 post-LCWE injection.
Cytokine Measurement by the Luminex
100 System
Cytokine levels in the plasma of KD patients and mice were
assessed using a commercially available Human and Mouse
Cytokine/Chemokine Milliplex
TM MAP kit (Millipore Corp.,
Billerica, MA) as follows: interleukin (IL)-2, IL-6, IL-10, monocyte
chemoattractant protein (MCP)-1, and tumor necrosis factor
(TNF)-a. This assay has been designed for the quantitative
measurement of multiple cytokines/chemokines in a single well
Figure 4. TLR2 and TLR4/MD2 surface expression in LCWE-treated mice. (A) Representative histograms showed surface expression of TLR2
and TLR4/MD2 by MFI on monocytes, neutrophils, and lymphocytes in the LCWE-treated mice and PBS-treated control mice on post-injection day 7.
The numbers labeled over the right upper quadrants indicated the representative percentage of TLR2
+ or TLR4/MD2
+ cells, corresponding to each cell
subpopulation. (B) The surface expression of TLR2 on circulating CD14
+ monocytes were analyzed by relative TLR2 MFI (rMFI=TLR2 MFI/isotype MFI)
at the indicated time points post-injection. (C) Circulating CD14
+ monocytes were significantly increased in LCWE-treated mice on days 3, 7, and 14
post injections. Values are expressed as mean6SME, n=7 mice/group per time point; *P,0.05; **P,0.01 versus PBS controls.
doi:10.1371/journal.pone.0038635.g004
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Luminex
100 Flowmetrix systems (Luminex Corp., Austin, TX).
Flow Cytometric Analysis
For analyzing the surface expression of TLR2 and TLR4, we
conducted double-stain of CD14/TLR2 and CD14/TLR4 in
human whole blood, and triple-stain of CD14/TLR2/TLR4 in
murine samples. Each staining reaction was incubated for
30 minutes with the following primary antibodies and their
corresponding isotypes (all from eBioscience, San Diego, CA) at
4uC as follows: fluorescein isothiocyanate (FITC)-conjugated anti-
human CD14, Phycoerythrin (PE)-conjugated anti-human TLR2,
PE-conjugated anti-human TLR4, allophycocyanin-labeled anti-
mouse CD14, biotin-conjugated anti-mouse TLR2 (subsequently
being labeled with streptavidin-peridinin-chlorophyll protein
complex), and PE-conjugated anti-mouse TLR4/MD2. After the
staining procedure, peripheral blood leukocytes (PBLs) were
isolated and then resuspended in 200 ml PBS containing 1%
paraformaldehyde for the flow cytometry analysis using FACSCa-
libur
H (Becton Dickinson, San Jose, CA). The percent expression
of CD14 was assessed using quadrants in the two-color mode. The
surface expression of TLR2 was calculated as the relative mean
fluorescence intensity (rMFI) normalized by the fluorescence
intensity of the isotype control in mice.
Histopathology
Murine cardiac tissues were fixed in formalin, and embedded in
paraffin. Coronary arteries and the nearby aortic valve were
serially identified (4 mm-thickness sections), and stained with
hematoxylin and eosin (H&E). Blinded microscopic assessment
by 2 pathologists was performed to identify coronary/aorta
arteritis, and/or myocarditis, depending upon the presence of
inflammatory infiltrates and damage to the cardiomyocytes and
vessel walls as well as valvulitis and pericarditis. In addition, the
lungs, spleens, livers, and kidneys were also excised for histopath-
ological examination.
Statistical Analysis
Data are presented as mean6SEM. The biochemical param-
eters of the murine samples and human TLR2 expression were
compared using Mann-Whitey U test. A standard 2-tailed t-test
was used for analyzing human plasma data and paired t-test was
used in comparison of pre-IVIG data to post-IVIG data. A P value
of ,0.05 determined using SPSS was considered statistically
significant.
Supporting Information
Figure S1 Effects of neutralizing anti-TLR2 (TLR2B)
and anti-TLR4 (TLR4) antibodies on LCWE-treated RAW
264.7 cells. IL-6, MCP-1, and TNF-a mRNA expression were
studied on RAW 264.7 cells. Data, presented as mean6SEM,
were derived from 3 independent experiments and normalized to
b-actin mRNA levels. *P,0.05 by Mann-Whitney U test.
(DOC)
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